Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Arizona.
Press releases published on September 5, 2025
5,000+ People Nationwide Turn to Virtual Program for Sciatica Relief
Sciatica Relief Now expands access to its movement-based, patient-led program created by PT Dean Volk, serving clients across the U.S. AZ, UNITED STATES, September 5, 2025 /EINPresswire.com/ -- As millions of Americans continue to live with sciatica …
Revive Therapeutics Announces Extension of Proposed Private Placement
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, …
Helios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul Gupta
Mobile, Alabama , Sept. 05, 2025 (GLOBE NEWSWIRE) -- Helios Alliance, a nonprofit dedicated to improving public health outcomes, announced today that Dr. Rahul Gupta, former director of the White House Office of National Drug Control Policy, will headline …
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, …
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société …
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock …
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to …
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to …
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …
Avania renforce son équipe de direction avec la nomination de quatre nouveaux dirigeants
BILTHOVEN, Pays-Bas et BOSTON, 05 sept. 2025 (GLOBE NEWSWIRE) -- Avania, le leader mondial du conseil et du développement clinique dans le secteur de la MedTech, a le plaisir d’annoncer la nomination stratégique de quatre dirigeants éminents. Alors que le …
Avania verstärkt Führungsteam mit der Ernennung von vier neuen Führungskräften
BILTHOVEN, Niederlande und BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avania, der weltweit führende Partner für Medizintechnikberatung und klinische Entwicklung, freut sich, die Ernennung von vier angesehenen Führungskräften in strategische …